data point call
despit pre-announc core growth declin vs weaker
expect well-below peer report mostli due fallout
china declin main end-market guidanc buy-back program
suspend plan temporari cost action support nt ep
wonder action leav less well-posit recoveri
recap growth vs weaker-than-expect mostli due
china exclud china core growth flat still low-end guid
account impact perspect despit end-mkt
mix variat much weaker tool peer report thru
march note core growth track
thru estimate impli declin final week
product instrument fell worst record vs recur rev
flat svc flat chemistri end-market pharma fell industri
eu us -msd china gov t/academ fell due widespread
 gave meaning commentari either april trend lightest month rang
pot outcom last week note would like
challeng geograph seen steadi recoveri china
pharma custom restart product back normal level yet
well pocket asia eu end-market expect pharma qa/qc
total pharma exposur stabl though pharma could lumpi part
due resourc re-alloc toward pgm servic mix usual
ballast stabil contract svc balanc on-demand svc
spare part could variabl far seen major order cancel
reduct underway buy-back suspend outlin plan realiz
cost save vs prior intern plan mostli aim opex via salari
cut discretionari spend cog spend cut equat total
opex come top workforc reduct done jan howev note
cost action temporari roll back next year suspens
buy-back also remov on-going sourc support stock/ep
china color china declin vs end-market pharma
mix industrial/food mix fell gov t/academ
weaker due univers closur linger
model chang maintain hold forecast core revenue declin trim
outlook revis ep factor expect cost
save off-set lower rev assum buyback pt
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
share repurchas
share repurchas
price target impli ev ebitda
recoveri industri global pharma capital-expenditure
strong uptak new product launch
share repurchas
price multipl ev
softer larg pharma budget stagnat recoveri
stepped-up invest restor top-lin growth
heighten competit pressur lc mass spec
price multipl ev
wat core focu three analyt technolog
concentr asset util disciplin
capit redeploy philosophi contribut
above-averag profit industry-lead
upsid case lean heavili success
upcom new product cycl recoveri china/
improv capit spend small molecul
pleas see import disclosur inform page report
pleas see import disclosur inform page report
water corporationhistor project valuat summarydollar million except per share amount fiscal year end decemb histor earn per flow cash cash flow cash flow per cash net interest free cash stock-bas sheet metricsreceiv day day day convers interest debt ttm debt ttm valu per water corpor jefferi llc estim equiti research
pleas see import disclosur inform page report
